Title: West African pre-pandemic cross-reactive antibody and cellular responses
against SARS-CoV-2
Authors: Bobby Brooke Herrera,¹⁻⁴ Beth Chaplin,⁴ Souleymane MBoup,⁵ Adam
Abdullahi,^{6,7} Michelle He,⁴ Sydney M. Fisher,⁴ Sulaimon Akanmu,⁸ Charlotte A Chang,⁴
Donald J Hamel,⁴ Ravindra K. Gupta,^{6,7} Phyllis J Kanki⁴

8 Affiliations:

- ⁹ ¹Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA
- ²Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases, and
- 11 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,
- 12 Rutgers University, New Brunswick, NJ, USA
- ¹³ ³Mir Biosciences, Inc., Dunellen, NJ, USA
- ⁴Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of
- 15 Public Health, Boston, MA, USA
- ⁵Institut de Recherche en Santé de Surveillance épidémiologique et de formation
- 17 (IRESSEF), Dakar, Senegal
- ⁶Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID),
- 19 Cambridge, UK ⁷Department of Medicine, University of Cambridge, Cambridge, UK
- ²⁰ ⁸Lagos University Teaching Hospital, College of Medicine, University of Lagos, Lagos,
- 21 Nigeria
- 22 **Correspondence:** PK, pkanki@hsph.harvard.edu

23 Abstract

24 The COVID-19 pandemic had a severe impact globally, yet African populations 25 exhibited unexpectedly lower rates of severe disease and mortality. We investigated the 26 potential role of pre-existing immunity in shaping the epidemiology of COVID-19 in 27 Africa. Leveraging paired plasma and peripheral blood mononuclear cells collected from 28 Senegalese female sex workers prior to the COVID-19 pandemic, we observed 29 substantial levels of pre-existing cross-reactive immunity to SARS-CoV-2, stemming 30 from prior exposure to seasonal human coronaviruses (hCoVs). Our antibody analysis revealed a 23.5% (47/200) seroprevalence rate against SARS-CoV-2 nucleocapsid (N). 31 Of these SARS-CoV-2 N-reactives, 85.1% (40/47), 44.7% (21/47), and 95.7% (45/47) 32 33 showed antibody reactivity against hCoV-229E or hCoV-OC43 spike (S) and/or N or hCoV-HKU1 S. Our analysis of cellular responses also demonstrated cross-reactivity to 34 35 SARS-CoV-2 with 82.2% (37/45) and 84.4% (38/45) showing IFN-y responses against S and N, respectively. These findings suggest that prior hCoV exposure may induce 36 37 cross-reactive adaptive immunity, potentially contributing to protection against COVID-19. A unique pre-pandemic subject had cross-reactive SARS-CoV-2 S antibodies with 38 39 detectable neutralization and cellular responses. Our study provides unique insights into 40 the dynamics of hCoV and SARS-CoV-2 immunity in West African populations and 41 underscores the importance of understanding the role of pre-existing immunity in 42 shaping COVID-19 outcomes globally.

43

44

46 Introduction

47 The first COVID-19 cases were recorded on the African continent in March 2020. yet by the end of the pandemic in May 2023, Africa's reported SARS-CoV-2 infections 48 49 and deaths constituted only 2-4% of the global disease burden despite being home to 50 ~17% of the world's population. Early projections of the COVID-19 pandemic's impact 51 on Africa predicted massive loss of life. Most African countries lacked adequate 52 healthcare infrastructure, workforce, and equipped facilities to cope with a novel and 53 highly infectious respiratory pathogen. However, other characteristics of most African countries suggested different outcomes from what was seen in resource-rich settings.¹ 54 55 Africa's relatively young population age distribution with lower rates of co-existing 56 morbidities, environmental factors, and pre-existing immunity from exposure to related 57 viruses may explain the unexpected low rates of severe disease and mortality observed in Africa.² 58

59 In 2020, SARS-CoV-2 emerged as a new human coronavirus, even though 60 worldwide populations were known to be regularly exposed to seasonal human 61 coronaviruses (hCoVs) responsible for the "common cold," including α -coronaviruses 62 (hCoV-229E, hCoV-NL63,) and β -coronaviruses (hCoV-OC43, hCoV-HKU1). Although associated with mild illness, these hCoVs share genetic similarity to the SARS 63 coronaviruses, which include SARS-CoV-1, SARS-CoV-2, and Middle East Respiratory 64 65 Syndrome (MERS). hCoVs are globally endemic and estimated to be responsible for up to 15-30% of pre-pandemic annual respiratory infections, which are seasonal (e.g., fall 66 67 and winter) and most prevalent in young children.

68 The widespread circulation of hCoVs with repeated exposure of human 69 populations and shared sequence homology to SARS-CoV-2 led to the suggestion that 70 hCoV immunologic memory could result in cross-reactive cellular and humoral 71 responses that might in part explain the heterogeneity of COVID-19 presenting 72 symptoms and pathogenic outcomes. While not providing sterilizing immunity, pre-73 existing hCoV immunity could reduce transmission and ameliorate symptoms of the 74 related SARS-CoV-2. Therefore, research has been conducted to determine the role of 75 pre-existing cross-reactive immunity to SARS-CoV-2. Multiple US and European studies 76 described CD4+ T cell reactivity in SARS-CoV-2 unexposed individuals, attributed to pre-existing memory responses to hCoVs.³⁻⁷ In a UK household study, exposed 77 78 contacts that remained PCR-negative showed significantly higher frequency of crossreactive (p=.0139) and nucleocapsid (N)-specific IL-2 secreting memory T cells 79 (p=.0355).³ Swadling et al. in a study of potentially abortive SARS-CoV-2 infection in UK 80 81 healthcare workers (HCWs) described pre-existing T cell reactivity directed against the 82 early transcribed replication-transcription complex (RTC).⁴ The RTC, consisting of RNA polymerase co-factor non-structural protein 7 (NSP7), RNA polymerase NSP12 and 83 84 helicase NSP13, is expressed early in the viral life cycle and is highly conserved among members of Coronaviridae.⁴ Studies of pre-pandemic samples collected from Africa 85 86 have also demonstrated cross-reactive T cell responses against several SARS-CoV-2 87 antigens.^{5,6} These studies have led to the hypothesis that prior hCoV infection might 88 provide protective cross-reactive memory, perhaps more likely in younger individuals in 89 whom infections with hCoVs are more prevalent and recent. As described by Lipsitch et 90 al., pre-existing cross-reactive memory T cells could lower respiratory tract viral load

91 thereby limiting the duration and severity of disease with potential to reduce viral
92 spread.⁷

93 Pre-existing antibody studies have also described distinct humoral responses to 94 SARS-CoV-2 associated with prior hCoV infection. Ng et al. described uninfected 95 donors with IgG reactivity to conserved epitopes in the S2 subunit of the SARS-CoV-2 96 spike (S) protein distinct from de novo humoral responses in infected individuals that 97 targeted both S1 and S2 subunits with concomitant IgM and IgA responses.⁸ Multiple 98 studies conducted in the US and Europe have identified antibodies to hCoVs (OC43) that were associated with lower risk of severe COVID-19.9, 10 99 Over the course of the COVID-19 pandemic in Africa, studies based on SARS-100

101 CoV-2 antibody detection described high prevalence rates of infection, in contrast with 102 surveillance data.¹¹ Yet, even with anticipated underreporting, severe COVID-19 cases and mortality remained unexpectedly low.¹² While multiple factors are likely to contribute 103 104 to the capacity of individuals to generate cross-reactivity, it is possible that the order and 105 composition of different infections may play a role in determining the efficacy of the 106 immune response in preventing symptomatic or severe COVID-19. Currently, high rates 107 of SARS-CoV-2 infection and COVID-19 vaccine exposure globally challenge the ability 108 to investigate cross-reactive responses in individuals who have not been exposed to 109 SARS-CoV-2. While our research group has reported on SARS-CoV-2 immune 110 responses in Nigeria,⁵ in this study we leveraged paired plasma and peripheral blood 111 monocular cell (PBMC) samples collected in Senegal, West Africa prior to the COVID-112 19 pandemic. Our objectives were to measure hCoV seroprevalence rates and to 113 characterize the pre-existing cross-reactive antibody and cellular responses to SARS-

114 CoV-2 in our pre-pandemic West African samples. The aim was to understand whether
115 and how pre-existing hCoV immunity might confer protection against severe COVID-19
116 disease in Africa.

117

118 Methods

119

120 Human samples:

121 The plasma and PBMC archive was developed from our multi-decade 122 prospective cohort study of HIV-1 and HIV-2 in Senegalese female sex workers (FSWs), followed from 1986-2010.¹³⁻¹⁵ Self-identified FSW routinely visiting a health 123 124 care clinic in Dakar provided blood samples to test for multiple sexually transmitted 125 infections, including HIV-1 and HIV-2 and were examined clinically; excess blood 126 samples were de-identified and archived with their corresponding clinical data. More 127 than 80% of women sampled were HIV negative and most had paired plasma and liquid 128 nitrogen preserved PBMCs with accompanying clinical and immunologic data at more 129 than 2 timepoints. The viability and functional integrity of these cryopreserved PBMCs have been previously demonstrated in our studies of HIV and flavivirus T-cell 130 131 immunity.¹⁶⁻¹⁸ The plasma and PBMC samples tested for this study were collected from 132 2004 to 2005. At the time of the original study, all women provided informed consent for 133 the collection and archiving of samples and corresponding data; ethical clearance from 134 the Harvard Institutional Review Board (IRB) and the research ethics committee at 135 Chiekh Anta Diop University, Dakar, Senegal were obtained. All archived samples and 136 corresponding data were anonymized, and as such this secondary analysis did not

137 constitute human subject research by institutional guidelines and regulations which138 follow the Federal Policy for Protection of Human Subjects.

139 Virion-based immunoblots:

We screened plasma samples by immunoblot assay on virion preparations from 140 SARS-CoV-2. Briefly, Vero E6 cells or susceptible cell line were infected with SARS-141 142 CoV-2 (Isolate USA-WA1/2020, BEI Resources NR-52281) or hCoVs (OC43, NL63, 143 229E, BEI Resources NR-5621, 470 and 52726, respectively) and propagated for five 144 days. Supernatants were clarified at 10,000g for 20min at 4°C, precipitated with PEG-145 8000 and NaCl, and then resolved by sucrose gradient ultracentrifugation at 170,000g 146 for 90min at 4°C. Viral pellets were lysed with complete NP40 buffer containing 147 protease inhibitors. Viral lysates were added to nonreducing buffer (final concentrations 148 of 2% SDS, 0.5 M Tris pH 6.8, 20% glycerol, 0.001% bromophenol blue) and subjected 149 to 12% PAGE and Western blot analysis using patient serum (1:250) as primary 150 antibody and anti-human IgG horseradish peroxidase (HRP) (1:2,000; ThermoFisher 151 Scientific, Waltham, MA) as secondary antibody. Visualization was performed using 152 Metal Enhanced DAB Substrate Kit (ThermoFisher Scientific, Waltham, MA) per the 153 manufacturer's instructions.

154 RecomLine SARS-CoV-2 IgG (Mikrogen)^{19, 20} is a CE-marked immunoblot assay 155 which determines the IgG responses towards the recombinant N antigens of the 156 seasonal hCoV 229E, OC43, NL63 and HKU-1 in parallel to SARS-CoV-2 N, receptor-157 binding domain (RBD), and S1 antigens.

158

159 ELISPOT assay:

160	ELISPOT assays were conducted as described previously ^{16, 21, 22} . In brief,
161	200,000 PBMCs per well were seeded in duplicate into 96-well plates coated with anti-
162	human IFN- γ (Becton Dickinson (BD), Franklin Lakes, NJ). The cells were stimulated
163	with fusion proteins consisting of a modified version of the Bacillus anthracis lethal
164	factor (LFn) and SARS- ²¹ CoV-2 S or N ((Mir Biosciences, Inc., Dunellen, NJ) and either
165	a negative (LFn alone, Mir Biosciences, Inc., Dunellen, NJ) or positive (PHA,
166	ThermoFisher, Waltham, MA) control at 37° C with 5% CO ₂ for 24 hours. LFn has been
167	shown to transport protein cargoes into the cell cytosol for MHC Class I and II
168	processing, inducing T cell responses. ^{16, 21, 22} After incubation, plates were washed
169	followed by incubation for 2 hours at room temperature with a secondary antibody (BD,
170	Franklin Lakes, NJ). Subsequently, plates were washed and incubated with streptavidin
171	(BD, Franklin Lakes, NJ) for 1 hour at room temperature. Finally, plates were washed
172	and incubated with substrate (BD, Franklin Lakes, NJ) for 30 minutes. IFN- γ spot
173	forming cells (SFC) were counted using the ImmunoSpot S6 Ultra M2 Analyzer ^{16, 21, 22}
174	(ImmunoSpot, Shaker Heights, OH)

175 Virus neutralization titer analyses

176

Pseudotype virus neutralization assay was performed on Hela-ACE2 cells using SARS-CoV-2 spike pseudotype virus (PV) expressing luciferase as previously described.^{23, 24} Briefly, dried plasma spots were eluted and heat inactivated at 54°C for 1 hour,²⁵ and incubated with PVs at 37°C for 1 hour prior to addition of Hela-ACE2 cells. The plasma dilution/virus mix was incubated for 48 hours in a 5% CO₂ environment at 37°C, and

182 luminescence was measured using the Bright-Glo Luciferase assay system (Promega 183 UK, United Kingdom). Neutralization was calculated relative to the virus and cell only 184 controls. Data was analyzed in GraphPad Prism v9.3.1 where 50% neutralization (ID₅₀) 185 values were calculated and the limit of detection for neutralization was set at ID₅₀ of 20 186 units.

187 Statistics

Bivariate analyses explored associations between select demographic
characteristics of the women with available data and SARS-CoV-2 N-reactive
immunoblot results. Demographic characteristics included: year of sampling, age at
sampling, neighborhood, ethnicity, country of origin, marital status, religion, education,
and total children. The chi-square test was used to obtain p-values to detect statistically
significant associations, and Fisher's exact test for categories with observed
frequencies ≤5.
Results
Results
Results Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV
Results Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV seroprevalence rates
Results Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV seroprevalence rates
Results Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV seroprevalence rates Pre-pandemic plasma samples (n=200) from the Senegalese FSW cohort were
Results Pre-pandemic cross-reactive SARS-CoV-2 antibody responses and hCoV seroprevalence rates Pre-pandemic plasma samples (n=200) from the Senegalese FSW cohort were analyzed for the presence of antibodies directed against SARS-CoV-2 S and/or N. 152

204	suggestive of prior exposure to hCoVs (Fig. 1, Fig. 2A). To determine hCoV
205	seroprevalence rates, the 47 samples reactive to SARS-CoV-2 N-only were analyzed
206	for antibodies directed against hCoV-229E S and N, hCoV-OC43 S and N, and hCoV-
207	HKU1 S. Of the samples tested, 37 (78.7%) samples showed reactivity to hCoV-229E
208	S <u>+</u> N, 7 (14.9%) to hCoV-OC43 S <u>+</u> N, and 45 (95.7%) to hCoV-HKU1 S (Fig. 1, Fig. 2B-
209	D). Of the 37 hCoV-229E S \pm N samples, 30 (81.1%) were reactive to S+N, while 7
210	(18.9%) were reactive to S-only. Of the 7 hCoV-OC43 S \pm N samples, 6 (85.7%) were
211	reactive to S+N, while 1 (14.3%) was reactive to S-only. Of note, 36 out of the 47
212	samples (76.6%) were reactive to both hCoV-229E S and hCoV-HKU1 S
213	(Supplementary Fig. 1). Only 6 (12.8%) were reactive to S of hCoV-229E, hCoV-OC43,
214	and hCoV-HKU1 (Supplementary Figs. 2-3).
215	

216 Risk factor analysis

Bivariate analysis of risk factors associated with SARS-CoV-2 N antibody reactivity included: year of sampling, age at sampling, neighborhood, ethnicity, country of origin, marital status, religion, education, and total children. There was a potential association between SARS-CoV-2 N-reactive and age >44 years (p=0.078) and with having \geq 3 children (p=0.044) (Table 1). Older age had a strong positive correlation with having more children.

223

224 Pre-pandemic cross-reactive T-cell responses to SARS-CoV-2

226	Of the 47 pre-pandemic samples that showed antibody reactivity to SARS-CoV-2
227	N-only and also antibody reactivity to hCoV S+N/S, 45 paired PBMCs were available,
228	along with 21 paired PBMCs from negative controls, and were analyzed for cross-
229	reactive IFN- γ cellular responses against SARS-CoV-2 S and N. Among SARS-CoV-2
230	N-reactives, 37 (82.2%) showed IFN-γ reactivity against SARS-CoV-2 S (Fig. 3A-B)
231	while 9 (19.6%) were negative. Similarly, 38 (84.4%) showed IFN- γ reactivity against
232	SARS-CoV-2 N (Fig. 3C-D) while 8 (17.4%) were negative. Among the 21 antibody
233	negative controls, 3 (14.3%) demonstrated weak IFN- γ cellular reactivity against both
234	SARS-CoV-2 S and N.
235	
236	Evidence for pre-pandemic SARS-CoV-2 variant
237	

In our initial serology, a single sample collected from a FSW in November 2004 238 239 demonstrated strong antibody reactivity to both SARS-CoV-2 S and N (Fig. 1A). 240 Longitudinal antibody analysis of 6 samples collected from this individual between 1997 to 2004 was conducted by SARS-CoV-2 immunoblot as well as the Mikrogen assay that 241 242 detected antibodies against the individual antigens of SARS-CoV-2 (S, RBD, and N) and hCoVs (HKU1, OC43, NL63, and 229E N). Samples collected in 1997 and 2001 showed 243 244 antibody reactivity to SARS-CoV-2 N-only by immunoblot with weak antibodies against 245 hCoVs, particularly in the 1997 sample (Fig. 4A-B). Seroconversion to SARS-CoV-2 S (2003) and S and RBD (May to November 2004) was observed by both immunoblot and 246 247 the Mikrogen assay, accompanied with stronger reactivity to hCoV-HKU1 N and hCoV-248 OC43 N. This seroprofile is unique from our other pre-pandemic serology and may

249 indicate exposure to a novel variant - one more closely related to SARS-CoV-2. 250 Additionally, longitudinal cellular responses were analyzed between 1997 and 2004. In 251 1997, this individual only had cellular responses against SARS-CoV-2 N. By 2001, this 252 individual had cellular responses against both SARS-CoV-2 S and N that persisted 253 throughout 2004 (Fig. 4C). Sequential analysis of SARS-CoV-2 neutralization revealed 254 no detectable neutralization response against SARS-COV-2 wild-type (Wu-1 614G) in 255 samples collected in 1997 and 2001 but showed detectable neutralization response in 256 samples collected in October 2003 (ID_{50} titer=281.3) with waning responses observed in 257 May 2004 (ID₅₀ titer=195.6); August 2004 (ID₅₀ titer=121.1) and November 2004 (ID₅₀ 258 titer=43.3). The observation of detectable responses coincided with seroconversion of S 259 and RBD antibodies reflecting exposure to hCoVs with possible cross-reactive potential 260 due to sequence homogeneity to a SARS-CoV-2 variant. Clinical examination data 261 collected as part of the prospective HIV clinical protocol did not indicate reporting of 262 symptoms or signs of respiratory disease, but the patient was noted to have lost 263 significant (>10%) weight between 2001 to 2003, during which S antibody seroconversion 264 occurred. The patient was also HIV-positive, 43 years of age in 2003, and had 3 living 265 children.

266

267 Discussion

268

In early 2021, we studied the immune responses in Nigerian healthcare workers
 (HCWs) at Lagos University Teaching Hospital (n=134) and in Oxford/AstraZeneca
 COVID-19 vaccine recipients from the general population (n=116) across five local

government areas (LGAs) in Lagos state.⁵ Antibodies directed to only SARS-CoV-2 N 272 273 in the absence of S antibody reactivity were detected in 9.7% (13/134) of HCWs and 274 15.5% (18/116) of the general population. This antibody profile directed to the SARS-275 CoV-2 N alone was suggestive of pre-existing cross-reactive immunity stemming from 276 prior hCoV infection. To investigate this possibility further, in this study we tested 277 archived plasma samples collected before the COVID-19 pandemic from our FSW 278 cohort in Dakar, Senegal (2004-2005), and observed 23.5% (47/200) of individuals with 279 pre-existing immunity to SARS-CoV-2 N-only (Fig. 1). Further testing demonstrated 280 prior infections with the seasonal hCoVs, providing evidence that the SARS-CoV-2 N-281 only reactivity resulted from cross-reactivity from prior hCoV exposure (Fig. 1-2). The 282 coronavirus N protein is more conserved than the S protein. As such, previously hCoV 283 exposed individuals can demonstrate cross-reactive N antibodies without cross-reactive S antibodies (Figs. 1-2).^{5, 26} 284

In one of the few studies conducted on samples from Africa prior to the COVID-285 286 19 pandemic, Tso et al. reported higher reactivity to hCoV N and S antigens with 287 significantly higher rates of cross-reactivity in Zambia (14.1%) and Tanzania (19%) compared to the US (2.4%).²⁷ In a multi-national study, Pedersen et al. reported higher 288 289 SARS-CoV-2 N reactivity in Gabon (20/116,17.2%) compared to reactivity in Canada, 290 Denmark, and Brazil. In samples from Senegal, largely from subjects under 17 years of 291 age, high antibody cross-reactivity to both S and N antigens of SARS-CoV-2 was observed; these samples failed to demonstrate in vitro neutralization.²⁶ Similar to this 292 Senegal study, our study also detected pre-pandemic antibody cross-reactivity to 293

SARS-CoV-2, but we concurrently detected cellular cross-reactivity to support theantibody results.

While most investigators study T cell responses to specific antigens using 296 297 overlapping peptides, we have used full-length antigens or large peptides fused to a 298 modified version of the Bacillus anthracis lethal factor (LFn). LFn has been shown to act 299 as a molecular shuttle, transporting antigens of interest into the cytosol for MHC Class I 300 and Class II processing for CD4+ and CD8+ T cell presentation. In the past, we have 301 used LFn to study T cell responses against several viruses, including HIV, Ebola, Zika, 302 dengue, and SARS-CoV-2.^{22-24,18} In our SARS-CoV-2 study of Nigerian HCWs and 303 individuals from the general population, among individuals with SARS-CoV-2 N-only 304 antibodies prior to vaccination, suggestive of prior exposure to hCoV, 81.8% (9/11) had 305 T cell responses to SARS-CoV-2 N. These results provided further evidence that 306 individuals who were previously exposed to hCoVs could have cross-reactive cellular responses against SARS-CoV-2. 307

308 Cross-reactive T cell responses play a protective role in protection against 309 COVID-19. Cellular responses were shown to map to cross-reactive recognition of 310 SARS-CoV-2 by T cells induced by hCoVs.²⁸⁻³¹ SARS-CoV-2-specific T cells were also 311 able to cross-react with SARS-CoV-1 and MERS-CoV.³²⁻³⁵ Recently, Tarke et al., 312 demonstrated that pre-pandemic samples collected from healthy adults in the US with 313 confirmed previous exposure to hCoV-NL63 and -OC43 had significant cross-reactive T 314 cell responses to SARS-CoV-2, particularly to conserved regions of SARS-CoV-2 S, N, nsp3, and nsp12.³⁶ Similarly, Namuniina et al. showed that in pre-pandemic samples 315 316 collected in Uganda, a majority of subjects had both CD4+ and/or CD8+ T cell

responses against SARS-CoV-2 S and non-S peptide pools.⁶ This study however did
not determine whether pre-existing immunity based on previous exposure to hCoV was
responsible for the cross-reactive cellular responses.

320 In the current study using pre-pandemic samples collected from Senegalese 321 FSWs, we show evidence of cellular cross-reactivity to SARS-CoV-2 with 82.2% (37/45) 322 and 84.4% (38/45) of PBMC samples matched to SARS-CoV-2 N antibody reactive plasma samples demonstrating IFN-y responses against S and N, respectively (Fig. 3). 323 324 Although these N antibody reactive samples showed no S antibody reactivity, the 325 majority demonstrated cross-reactive cellular responses to both SARS-CoV-2 S and N, 326 suggesting that cellular responses against this less conserved region may be more 327 sustained over time than humoral responses. Among the SARS-CoV-2 negative 328 controls, a majority (18/21, 85.7%) did not have cellular responses. However, three 329 control individuals showed weak cellular responses against SARS-CoV-2 S and N. This 330 again may reflect the more temporal nature of humoral immunity compared with the 331 longevity of cellular immunity. Additionally, the individual that initially tested antibody positive for SARS-CoV-2 S-only also had sustained cross-reactive cellular responses to 332 333 SARS-CoV-2 S and/or N from 1997 to 2004 (Fig. 4C) with evidence of sustained albeit waning neutralization responses from 2003 and 2004 (Fig. 4D). 334

It is unknown whether these cross-reactive cellular responses from prior hCoV infection were sustained at levels that would impact the pathogenesis of SARS-CoV-2 during the 2020 pandemic. Immunologic memory to antigenically related infections can result in both positive and negative patient outcomes. As described in influenza, the induction of antibody responses to new virus infection can "backboost" responses to

340	preceding heterologous viruses. ³⁷ In contrast, prior heterologous responses with
341	reduced functionality may misdirect new responses resulting in negative clinical
342	outcomes, i.e. "original antigenic sin" ^{38, 39} , particularly in antigenically shifting viruses
343	such as SARS COV-2. Our results show significant prior hCoV infection with
344	demonstrable antibodies to SARS-CoV-2 N and cellular responses to S and N, which
345	when taken in consideration with low rates of severe COVID-19 disease and mortality in
346	Africa, suggest through indirect association the possibility that prior hCoV infection
347	provides cross-reactive protective immunity in SARS-CoV-2 infection.
348	In our risk factor analysis, we saw potential higher risk of SARS-CoV-2 N
349	reactivity, suggesting previous hCoV infection, in women who were >44 years of age
350	and who had ≥3 children. This might be explained by older women having had more

children, and therefore increased exposure to respiratory illnesses from young and 352 school-aged children amongst whom susceptibility to infection and transmission may be 353 highest.

351

354 Our study of pre-pandemic immunologic reactivity to SARS-CoV-2 in Senegal is 355 unique in its assessment of both antibody and cellular responses. However, our study 356 has limitations. We were unable to evaluate the cellular immune responses to hCoVs to 357 verify the proposed source of SARS CoV-2 cross-reactive IFN-y cellular responses. Our 358 assessment of primary hCoV infection was based on serologic reactivity to hCoV S, 359 which may not be diagnostic of hCoV infection or correlate with hCoV N reactivity or 360 cross-reactivity to SARS-CoV-2 N. We were unable to directly test our hypothesis by 361 demonstrating that a significant fraction of the population possessed antibody and 362 cellular cross-reactive immune responses to SARS-CoV-2 at the time of the pandemic.

Also, our study analyzed samples from only adult females, who may have differentimmune responses than males and children.

365	Altogether, our study uniquely analyzed both antibody and cellular responses in
366	West Africans, demonstrating that pre-existing immunity against hCoVs can induce
367	cross-reactive T cell responses against SARS-CoV-2. The concurrent measurement of
368	cross-reactive immune responses from both the antibody and cellular arms of the
369	adaptive response provides additional support to the hypothesis that pre-existing hCoV
370	adaptive immunity might impact SARS CoV-2 pathogenesis. These data provide
371	valuable insights toward a clearer understanding of the dynamics of SARS-CoV-2
372	disease progression and protection in the West African setting.
373	

374 Role of the funding source

Authors declare that the funder did not have any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

378

379 References

Blanton RE, Mock NB, Hiruy HN, Schieffelin JS, Doumbia S, Happi C, Samuels
 RJ, Oberhelman RA. African Resources and the Promise of Resilience against COVID 19. Am J Trop Med Hyg. 2020. Epub 2020/06/06. doi: 10.4269/ajtmh.20-0470. PubMed
 PMID: 32500851.

Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R,
 Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo

E. Rotich T. Orgut I. Kihara S. Otiende M, Bottomley C, Mupe ZN, Kagucia EW, 386 387 Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, 388 Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott 389 JAG, Warimwe GM. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan 390 blood donors. Science. 2020. Epub 2020/11/13. doi: 10.1126/science.abe1916. 391 PubMed PMID: 33177105. 392 3. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, Conibear E, 393 Koycheva A, Davies M, Tolosa-Wright M, Hakki S, Varro R, McDermott E, Hammett S, 394 Cutajar J, Thwaites RS, Parker E, Rosadas C, McClure M, Tedder R, Taylor GP, 395 Dunning J, Lalvani A. Cross-reactive memory T cells associate with protection against 396 SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13(1):80. Epub 397 20220110. doi: 10.1038/s41467-021-27674-x. PubMed PMID: 35013199; PMCID: PMC8748880. 398 Swadling L. Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, 399 4.

Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S,

401 Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE,

402 Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA,

403 Moon JC, Investigators CO, van Dorp L, Balloux F, McKnight A, Noursadeghi M,

404 Bertoletti A, Maini MK. Pre-existing polymerase-specific T cells expand in abortive

405 seronegative SARS-CoV-2. Nature. 2022;601(7891):110-7. Epub 20211110. doi:

406 10.1038/s41586-021-04186-8. PubMed PMID: 34758478; PMCID: PMC8732273.

407 5. Akanmu AS, Herrera BB, Chaplin B, Ogunsola F, Oshibogun A, Onawoga F,

408 John-Olabode S, Akase IE, Nwosu A, Hamel DJ, Chang CA, Kanki PJ. High SARS-

409 CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular responses. J 410 Clin Viro Plus. 2023;3(3):100156. doi: https://doi.org/10.1016/j.jcvp. 2023.100156. 411 6. Namuniina A, Muyania ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, 412 Hills N, Nanteza A, Bagaya BS, Weiskopf D, Riou C, Reynolds SJ, Galiwango RM, 413 Redd AD. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive 414 CD4+ and CD8+ T-cell responses: A pilot study. PLOS Glob Public Health. 2023;3(8):e0001566. Epub 20230816. doi: 10.1371/journal.pgph.0001566. PubMed 415 416 PMID: 37585383; PMCID: PMC10431628. 417 7. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol. 2020;20(11):709-13. Epub 2020/10/08. 418 419 doi: 10.1038/s41577-020-00460-4. PubMed PMID: 33024281; PMCID: PMC7537578. 420 8. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson 421 P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, 422 423 Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, 424 Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, 425 Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, 426 Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. Preexisting and de 427 novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43. 428 Epub 20201106. doi: 10.1126/science.abe1107. PubMed PMID: 33159009; PMCID: 429 PMC7857411. Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer AE, Hanses F, 430 9. 431 Vollenberg R, Lorentzen E, Tiwari-Heckler S, Duchemin J, Ellouze S, Vetter M, Furst J,

432 Schuster P, Brix T, Denkinger CM, Muller-Hoow C, Schmidt H, Tepasse	SSE PR, KUNN J.
---	-----------------

- 433 Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies
- 434 patients at risk of critical COVID-19. J Clin Virol. 2021;139:104847. Epub 20210424.
- doi: 10.1016/j.jcv.2021.104847. PubMed PMID: 33965698; PMCID: PMC8065244.
- 436 10. Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H,
- 437 Tepasse PR, Kuhn J. Less severe course of COVID-19 is associated with elevated
- 438 levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV
- 439 OC43, HCoV HKU1). Int J Infect Dis. 2021;105:304-6. Epub 20210223. doi:
- 440 10.1016/j.ijid.2021.02.085. PubMed PMID: 33636357; PMCID: PMC7901274.
- 441 11. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, Valenciano M,
- 442 Cheng B, Noel K, Cao C, Yanes-Lane M, Herring BL, Talisuna A, Ngoy N, Balde T,
- 443 Clifton D, Van Kerkhove MD, Buckeridge D, Bobrovitz N, Okeibunor J, Arora RK,
- Bergeri I, Group USC. SARS-CoV-2 infection in Africa: a systematic review and meta-
- analysis of standardised seroprevalence studies, from January 2020 to December 2021.
- 446 BMJ Glob Health. 2022;7(8). doi: 10.1136/bmjgh-2022-008793. PubMed PMID:
- 447 35998978; PMCID: PMC9402450.
- 448 12. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev
- 449 Immunol. 2021;21(8):469-70. Epub 20210624. doi: 10.1038/s41577-021-00579-y.
- 450 PubMed PMID: 34168345; PMCID: PMC8222946.
- 451 13. Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, Siby T, Thior I,
- 452 Hernandez-Avila M, Sankale JL, et al. Slower heterosexual spread of HIV-2 than HIV-1.
- 453 Lancet. 1994;343(8903):943-6. doi: 10.1016/s0140-6736(94)90065-5. PubMed PMID:
- 454 7909009.

455	14. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia					
456	MC, Gueye EH, et al. Reduced rate of disease development after HIV-2 infection as					
457	compared to HIV-1. Science. 1994;265(5178):1587-90. doi: 10.1126/science.7915856.					
458	PubMed PMID: 7915856.					
459	15. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup					
460	S, Kanki PJ. Twenty years of prospective molecular epidemiology in Senegal: changes					
461	in HIV diversity. AIDS Res Hum Retroviruses. 2007;23(10):1189-96. doi:					
462	10.1089/aid.2007.0037. PubMed PMID: 17961103.					
463	16. Herrera BB, Tsai WY, Chang CA, Hamel DJ, Wang WK, Lu Y, Mboup S, Kanki					
464	PJ. Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus					
465	NS3 in West Africa. J Virol. 2018;92(7). Epub 2018/01/13. doi: 10.1128/jvi.01992-17.					
466	PubMed PMID: 29321308; PMCID: PMC5972862.					
467	17. Sarr AD, Lu Y, Sankale JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H.					
468	Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-					
469	based enzyme-linked immunospot assay. AIDS Res Hum Retroviruses.					
470	2001;17(13):1257-64. doi: 10.1089/088922201750461311. PubMed PMID: 11559425.					
471	18. Hanson A, Sarr AD, Shea A, Jones N, Mboup S, Kanki P, Cao H. Distinct profile					
472	of T cell activation in HIV type 2 compared to HIV type 1 infection: differential					
473	mechanism for immunoprotection. AIDS Res Hum Retroviruses. 2005;21(9):791-8. doi:					
474	10.1089/aid.2005.21.791. PubMed PMID: 16218803.					
475	19. Bauer G. The variability of the serological response to SARS-corona virus-2:					
476	Potential resolution of ambiguity through determination of avidity (functional affinity). J					

477 Med Virol. 2021;93(1):311-22. Epub 20200715. doi: 10.1002/jmv.26262. PubMed PMID:
478 32633840; PMCID: PMC7361859.

20. Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E,

480 Motz M, Bauer G. Incomplete IgG avidity maturation after seasonal coronavirus

481 infections. J Med Virol. 2022;94(1):186-96. Epub 20210827. doi: 10.1002/jmv.27291.

482 PubMed PMID: 34427932.

483 21. Herrera BB, Hamel DJ, Oshun P, Akinsola R, Akanmu AS, Chang CA, Eromon

484 P, Folarin O, Adeyemi KT, Happi CT, Lu Y, Ogunsola F, Kanki PJ. A modified anthrax

485 toxin-based enzyme-linked immunospot assay reveals robust T cell responses in

486 symptomatic and asymptomatic Ebola virus exposed individuals. PLoS Negl Trop Dis.

487 2018;12(5):e0006530. Epub 2018/05/26. doi: 10.1371/journal.pntd.0006530. PubMed

488 PMID: 29795572; PMCID: PMC5991402.

489 22. Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, Wang WK, Kanki

490 PJ. T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and

491 Zika Viruses. MBio. 2018;9(4). doi: 10.1128/mBio.00755-18. PubMed PMID: 30087165;

492 PMCID: PMC6083909.

493 23. Abdullahi A, Oladele D, Owusu M, Kemp SA, Ayorinde J, Salako A, Fink D, Ige

494 F, Ferreira I, Meng B, Sylverken AA, Onwuamah C, Boadu KO, Osuolale K, Frimpong

495 JO, Abubakar R, Okuruawe A, Abdullahi HW, Liboro G, Agyemang LD, Ayisi-Boateng

496 NK, Odubela O, Ohihoin G, Ezechi O, Kamasah JS, Ameyaw E, Arthur J, Kyei DB,

497 Owusu DO, Usman O, Mogaji S, Dada A, Agyei G, Ebrahimi S, Gutierrez LC, Aliyu SH,

498 Doffinger R, Audu R, Adegbola R, Mlcochova P, Phillips RO, Solako BL, Gupta RK.

499 SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nat

500 Commun. 2022;13(1):6131. Epub 20221017. doi: 10.1038/s41467-022-33792-x.

501 PubMed PMID: 36253377; PMCID: PMC9574797.

502 24. Abdullahi A, Frimpong J, Cheng MTK, Aliyu SH, Smith C, Abimiku A, Phillips RO,

503 Owusu M, Gupta RK. Performance of SARS COV-2 IgG Anti-N as an Independent

504 Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population. Am J

505 Trop Med Hyg. 2023;109(4):890-4. Epub 20230814. doi: 10.4269/ajtmh.23-0179.

506 PubMed PMID: 37580023; PMCID: PMC10551093.

507 25. Wong MP, Meas MA, Adams C, Hernandez S, Green V, Montoya M, Hirsch BM,

Horton M, Quach HL, Quach DL, Shao X, Fedrigo I, Zermeno A, Huffaker J, Montes R,

509 Madden A, Cyrus S, McDowell D, Williamson P, Contestable P, Stone M, Coloma J,

510 Busch MP, Barcellos LF, Harris E. Development and Implementation of Dried Blood

511 Spot-Based COVID-19 Serological Assays for Epidemiologic Studies. Microbiol Spectr.

512 2022;10(3):e0247121. Epub 20220525. doi: 10.1128/spectrum.02471-21. PubMed

513 PMID: 35612315; PMCID: PMC9241704.

514 26. Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, Diagne

515 CT, Dia N, Naghibosadat M, McGeer A, Muberaka S, Moukandja IP, Ndidi S, Tauil CB,

516 Lekana-Douki JB, Loucoubar C, Faye O, Sall A, Magalhaes KG, Weis N, Kozak R,

517 Kobinger GP, Fausther-Bovendo H. Cross-reactive immunity against SARS-CoV-2 N

518 protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep.

519 2022;12(1):12962. Epub 20220728. doi: 10.1038/s41598-022-17241-9. PubMed PMID:

520 35902675; PMCID: PMC9333058.

521 27. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, Ngalamika

522 O, Julius P, West JT, Wood C. High prevalence of pre-existing serological cross-

- 523 reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
- sub-Saharan Africa. Int J Infect Dis. 2021;102:577-83. Epub 20201108. doi:
- 525 10.1016/j.ijid.2020.10.104. PubMed PMID: 33176202; PMCID: PMC7648883.
- 526 28. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC,
- 527 Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L,
- 528 Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ,
- 529 Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. Selective and cross-
- 530 reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science.
- 531 2020;370(6512):89-94. Epub 20200804. doi: 10.1126/science.abd3871. PubMed PMID:
- 532 32753554; PMCID: PMC7574914.
- 533 29. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T,
- 534 Mangold M, Unger C, Dorfler F, Kadler S, Rosowski J, Gurcan K, Uyar-Aydin Z,
- 535 Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, Muller MA,
- 536 Sawitzki B, Miltenyi S, Paul F, Mall MA, Wenschuh H, Voigt S, Drosten C, Lauster R,
- Lachman N, Sander LE, Corman VM, Rohmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel
- 538 C. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon
- 539 infection and vaccination. Science. 2021;374(6564):eabh1823. Epub 20211008. doi:
- 540 10.1126/science.abh1823. PubMed PMID: 34465633; PMCID: PMC10026850.
- 541 30. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lubke M,
- 542 Bauer J, Rieth J, Wacker M, Peter A, Horber S, Traenkle B, Kaiser PD, Rothbauer U,
- 543 Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos
- 544 TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jager
- 545 E, Graf M, Gruber LC, Rachfalski D, Preuss B, Hagelstein I, Marklin M, Bakchoul T,

546	Gouttefangeas C, Kohlbacher O, Klein R, Stevanovic S, Rammensee HG, Walz JS.						
547	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell						
548	recognition. Nat Immunol. 2021;22(1):74-85. Epub 20200930. doi: 10.1038/s41590-020-						
549	00808-x. PubMed PMID: 32999467.						
550	31. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY,						
551	Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah						
552	PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of						
553	COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-62. Epub						
554	2020/07/16. doi: 10.1038/s41586-020-2550-z. PubMed PMID: 32668444.						
555	32. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence						
556	Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune						
557	Responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671-80 e2. Epub 20200316.						
558	doi: 10.1016/j.chom.2020.03.002. PubMed PMID: 32183941; PMCID: PMC7142693.						
559	33. Habel JR, Nguyen THO, van de Sandt CE, Juno JA, Chaurasia P, Wragg K,						
560	Koutsakos M, Hensen L, Jia X, Chua B, Zhang W, Tan HX, Flanagan KL, Doolan DL,						
561	Torresi J, Chen W, Wakim LM, Cheng AC, Doherty PC, Petersen J, Rossjohn J,						
562	Wheatley AK, Kent SJ, Rowntree LC, Kedzierska K. Suboptimal SARS-CoV-2-specific						
563	CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype. Proc						
564	Natl Acad Sci U S A. 2020;117(39):24384-91. Epub 20200910. doi:						
565	10.1073/pnas.2015486117. PubMed PMID: 32913053; PMCID: PMC7533701.						
566	34. Prakash S, Srivastava R, Coulon PG, Dhanushkodi NR, Chentoufi AA, Tifrea DF,						
567	Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Buchmeier MJ, Bouziane M, Nesburn						
568	AB, Kuppermann BD, BenMohamed L. Genome-Wide B Cell, CD4(+), and CD8(+) T						

- 569 Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses,
- 570 Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. J
- 571 Immunol. 2021;206(11):2566-82. Epub 20210428. doi: 10.4049/jimmunol.2001438.
- 572 PubMed PMID: 33911008; PMCID: PMC8722450.
- 573 35. Rha B, Lively JY, Englund JA, Staat MA, Weinberg GA, Selvarangan R, Halasa
- 574 NB, Williams JV, Boom JA, Sahni LC, Michaels MG, Stewart LS, Harrison CJ, Szilagyi
- 575 PG, McNeal MM, Klein EJ, Strelitz B, Lacombe K, Schlaudecker E, Moffatt ME,
- 576 Schuster JE, Pahud BA, Weddle G, Hickey RW, Avadhanula V, Wikswo ME, Hall AJ,
- 577 Curns AT, Gerber SI, Langley G. Severe Acute Respiratory Syndrome Coronavirus 2
- 578 Infections in Children: Multicenter Surveillance, United States, January-March 2020. J
- 579 Pediatric Infect Dis Soc. 2020;9(5):609-12. doi: 10.1093/jpids/piaa075. PubMed PMID:
- 580 32556327; PMCID: PMC7337823.
- 581 36. Tarke A, Zhang Y, Methot N, Narowski TM, Phillips E, Mallal S, Frazier A, Filaci
- 582 G, Weiskopf D, Dan JM, Premkumar L, Scheuermann RH, Sette A, Grifoni A. Targets
- and cross-reactivity of human T cell recognition of Common Cold Coronaviruses.
- 584 bioRxiv. 2023. Epub 20230105. doi: 10.1101/2023.01.04.522794. PubMed PMID:
- 585 36656777; PMCID: PMC9844015.
- 586 37. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones
- 587 TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le
- 588 TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N,
- de Jong JC, Palache A, Beyer WEP, Le QM, Nguyen TH, Wertheim HFL, Hurt AC,
- 590 Osterhaus A, Barr IG, Fouchier RAM, Horby PW, Smith DJ. Antibody landscapes after

- influenza virus infection or vaccination. Science. 2014;346(6212):996-1000. doi:
- 592 10.1126/science.1256427. PubMed PMID: 25414313; PMCID: PMC4246172.
- 593 38. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate
- 594 leukocytes. Nature. 1977;265(5596):739-41. PubMed PMID: 404559.
- 39. Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD,
- 596 Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA,
- van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans
- 598 MP, van Nierop GP. Seasonal coronavirus-specific B cells with limited SARS-CoV-2
- 599 cross-reactivity dominate the IgG response in severe COVID-19. The Journal of clinical
- 600 investigation. 2021;131(21). doi: 10.1172/JCI150613. PubMed PMID: 34499051;
- 601 PMCID: PMC8553556.



Fig. 1. SARS-CoV-2 and hCoVs seroprevalence rates. A) Schematic representation of serology workflow. *, Samples were analyzed against hCoV-HKU1 S only. B) 200 samples were initially tested against SARS-CoV-2 S and N; 47 samples had antibodies against SARS-CoV-2 N-only (blue donut chart). These 47 samples were then tested against hCoV-229E S and N (green donut chart), hCoV-OC43 S and N (purple donut chart), and hCoV-HKU1 S (yellow donut chart).



Fig. 2. SARS-CoV-2 and hCoV antibody cross-reactive in samples collected pre-pandemic. Plasma collected from FSWs prior to the COVID-19 pandemic were subjected to immunoblot analysis. Representative images of immunoblots for samples that had antibodies for A) SARS-CoV-2 N-only or were negative, B) hCoV-229E S+N/S-only, N-only, or were negative, C) hCoV-OC43 S+N, N-only, or were negative, and D) hCoV-HKU1 S or were negative.

	N rea	active	N non-	reactive	Chi-square* p-
	No.	%	No.	%	value
Year of sampling					
2004	74	81.3%	17	18.7%	0.142
2005	79	72.5%	30	27.5%	
Age at sampling					
≤44 years	92	76.0%	29	24.0%	0.078
>44 years	22	61.1%	14	38.9%	
Neighborhood					
Dakar	82	75.2%	27	24.8%	0.582
Outside Dakar	37	71.2%	15	28.8%	
Ethnicity					
Wolof	47	78.3%	13	21.7%	0.188
Other	68	68.7%	31	31.3%	
Country of origin					
Senegal	106	73.1%	39	26.9%	0.535*
Other	9	64.3%	5	35.7%	
Marital status					
Single	34	77.3%	10	22.7%	0.578*
Divorced	64	71.9%	25	28.1%	
Widowed	7	63.6%	4	36.4%	
Religion					
Muslim	94	73.4%	34	26.6%	0.767*
Christian	11	68.8%	5	31.3%	
Education					
None	43	69.4%	19	30.6%	0.428
1-6 years	30	81.1%	7	18.9%	
7-14 years	30	71.4%	12	28.6%	
Total children					
0-2	70	78.7%	19	21.3%	0.044
≥3	45	64.3%	25	35.7%	

Table 1. Associations between baseline characteristics and SARS-CoV-2 nucleocapsid (N) antibody reactivity (N=200¹)

¹ 200 samples tested: 47 SARS-CoV-2 N positive, 153 SARS-CoV-2 N negative. 159 had baseline record.

*Fisher's exact test was used for variables with cells with observed frequencies ≤5.



Fig. 3. Cross-reactive SARS-CoV-2 cellular responses in samples collected pre-pandemic. PBMCs collected from FSWs prior to the COVID-19 pandemic were stimulated with A) LFn-SARS-CoV-2 S or B) LFn-SARS-CoV-2 N and IFN-y responses were detected by ELISPOT. SFC, spot forming cells. Black dotted lines, LFn-SARS-CoV-2 S and N cutoffs.

Α



Fig. 4. Evidence for pre-pandemic SARS-CoV-2 variant. Longitudinally collected plasma samples collected from a FSW between 1997 and 2004 were subjected to A) SARS-CoV-2 immunoblots or the commercial B) Mikrogen assay. C) Paired PBMCs samples were stimulated with LFn-SARS-CoV-2 S or LFn-SARS-CoV-2 N and IFN- γ responses were detected by ELISPOT. SFC, spot forming cells. Light blue dotted line, LFn-SARS-CoV-2 S cutoff. Dark blue dotted line, , LFn-SARS-CoV-2 N cutoff. D) Plasma neutralization (Log10) of pseudotype virus against SARS COV-2 Wild type (Wu-1) in one individual with longitudinal samples collected between 1997 and 2004 including two positive controls from SARS CoV-2 infected and vaccinated adults in 2021 and prepandemic human sera as negative control. Results displayed under the x-axis correspond to their antibody reactivity via immublot assays.



				229E		
		S-only	S+N	N-only	Negative	TOTAL
	S-only		1			1
	S+N*		5	1		6
OC43	N-only	2	18	2	3	25
	Negative	5	5		3	13
	TOTAL	7	29	3	6	45

Supplementary Fig. 1. Overlap in reactivity between hCoV-229E and hCoV-OC43.

Supplementary Fig. 2. Overlap in reactivity between hCoV-229E S and hCoV-HKU1 S.

				229E		_
		S-only	S+N	N-only	Negative	TOTAL
	Spike-reactive	7	29	3	6	45
HKU-1 S	Negative		1		1	2
	TOTAL	7	30	3	7	47

Supplementary Fig. 3. Overlap in reactivity between hCoV-OC43 S and hCoV-HKU1 S.

		OC43				
		S-only	S+N	N-only	Negative	TOTAL
HKU-1 S	Spike-reactive	1	6	25	13	45
	Negative			1	1	2
	TOTAL	1	6	26	14	47